Tvardi Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
HOUSTON--(BUSINESS WIRE)--Jan 5, 2023--
Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, in San Francisco, CA.
Date: Tuesday, January 10, 2023
Time: 5:30 p.m. PST
Location: The Westin St. Francis – Mission Bay (32nd Floor)
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of relapsed/refractory patients with advanced solid tumors. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit https://tvarditherapeutics.com/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230105005185/en/
CONTACT: Tvardi Investor Relations
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: Tvardi Therapeutics, Inc.
Copyright Business Wire 2023.
PUB: 01/05/2023 09:00 AM/DISC: 01/05/2023 09:01 AM